A detailed history of Redmile Group, LLC transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 3,065,714 shares of ADGI stock, worth $10.1 Million. This represents 0.66% of its overall portfolio holdings.

Number of Shares
3,065,714
Previous 3,065,714 -0.0%
Holding current value
$10.1 Million
Previous $10.1 Million -0.0%
% of portfolio
0.66%
Previous 0.66%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
N/A
1,624,989 Added 112.79%
3,065,714 $10.1 Million
Q4 2022

Feb 14, 2023

SELL
$3.08 - $4.05 $1.48 Million - $1.94 Million
-480,235 Reduced 25.0%
1,440,725 $4.77 Million
Q4 2021

Feb 14, 2022

SELL
$6.35 - $47.04 $8.42 Million - $62.4 Million
-1,326,000 Reduced 40.84%
1,920,960 $13.9 Million
Q3 2021

Nov 15, 2021

BUY
$20.88 - $56.08 $67.8 Million - $182 Million
3,246,960 New
3,246,960 $137 Million

Others Institutions Holding ADGI

About Adagio Therapeutics, Inc.


  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.